STRO compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

STROSutro Biopharma, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

STROSutro Biopharma, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

STRO: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only STRO 16

—Stanfordunlistedsupplier

—Alemany Plazaunlistedsupplier

—Five Prime Therapeuticsunlistedsupplier

—Jefferiesunlistedsupplier

12 more · STRO chain ›

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

STROSutro Biopharma, Inc.

9.64▲+1.40%

Mkt cap$157.7MRevenue$10MQ2 FY26Revenue$102MFY25

AMGNAmgen Inc

478.30▲+3.69%

Regular sessionNov 4 '26

Mkt cap$249.4BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Regular sessionNov 4 '26

STROSutro Biopharma, Inc.

AMGNAmgen Inc

9.64▲+1.40%

Price

478.30▲+3.69%

$157.7M

Mkt cap

$249.4B

Q2 FY26$10M

Revenue

$10.4BQ3 FY26

FY25$102M

Revenue

$36.8BFY25

STRO9.64▲+1.40%vsAMGN478.30▲+3.69%Regular sessionNov 4 '26

Price

rebased to 0%

STRO, solidAMGN, dashed